RANDOMIZED, PARTIAL BLIND STUDY OF THE PHARMACODYNAMICS, PHARMACOKINETICS AND SAFETY OF MULTIPLE SUBCUTANEOUS DOSES OF ALIROCUMAB, A FULLY HUMAN MONOCLONAL ANTIBODY TO PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9, ADMINISTERED EVERY 4 WEEKS ALONE OR IN COMBINATION WITH EZETIMIBE OR FENOFIBRATE IN HEALTHY SUBJECTS

Authors
Category Primary study
JournalJOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
Year 2014
This article has no abstract
Epistemonikos ID: 1e1e01a9518130c5ccd7af1e5e4819669d37ecb8
First added on: Feb 05, 2025